Abstract
A growing literature suggests the association of low tissue levels and/or dietary intake of n-polyunsaturated fatty acids (PUFA) with depressive illnesses. Animal studies show that low tissue and/or dietary n-3 PUFAs can lead to behaviors and neurobiological effects associated with depression and can potentiate the consequences of stress, whereas higher levels have the opposite effect. These data support the involvement of n-3 PUFAs levels in the disease processes underlying depression. In addition, these pre-clinical findings indicate neurobiological mechanisms whereby n-3 PUFAs may contribute to the disease including control of serotonergic and dopaminergic function, modulation of brain-derived neurotrophic factor (BDNF) in the hippocampus, regulation of the hypothalamic-pituitary-adrenal axis, and effects on neuroinflammation. This evidence for a role for n-3 PUFA in the pathophysiology and treatment of depressive illness are reviewed. The implications of these finding for future pre-clinical research and clinical application are discussed.
Keywords: Brain-derived neurotrophic factor, corticosterone, docosahexaenoic acid, dopamine, elevated plus maze, forced swim test, neuroimmune, serotonin.
CNS & Neurological Disorders - Drug Targets
Title:N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
Volume: 12 Issue: 4
Author(s): Beth Levant
Affiliation:
Keywords: Brain-derived neurotrophic factor, corticosterone, docosahexaenoic acid, dopamine, elevated plus maze, forced swim test, neuroimmune, serotonin.
Abstract: A growing literature suggests the association of low tissue levels and/or dietary intake of n-polyunsaturated fatty acids (PUFA) with depressive illnesses. Animal studies show that low tissue and/or dietary n-3 PUFAs can lead to behaviors and neurobiological effects associated with depression and can potentiate the consequences of stress, whereas higher levels have the opposite effect. These data support the involvement of n-3 PUFAs levels in the disease processes underlying depression. In addition, these pre-clinical findings indicate neurobiological mechanisms whereby n-3 PUFAs may contribute to the disease including control of serotonergic and dopaminergic function, modulation of brain-derived neurotrophic factor (BDNF) in the hippocampus, regulation of the hypothalamic-pituitary-adrenal axis, and effects on neuroinflammation. This evidence for a role for n-3 PUFA in the pathophysiology and treatment of depressive illness are reviewed. The implications of these finding for future pre-clinical research and clinical application are discussed.
Export Options
About this article
Cite this article as:
Levant Beth, N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence, CNS & Neurological Disorders - Drug Targets 2013; 12 (4) . https://dx.doi.org/10.2174/1871527311312040003
DOI https://dx.doi.org/10.2174/1871527311312040003 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Non-viral Gene Therapy Strategies for the Treatment of Glioblastoma
Current Medicinal Chemistry Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design New Preparative Approaches for Micro and Nano Drug Delivery Carriers
Current Drug Delivery Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimer’s Disease
Current Alzheimer Research Pharmacological Roles of the Large-Conductance Calcium-Activated Potassium Channel
Current Topics in Medicinal Chemistry Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Early Development of Sea Urchin P.lividus Under Static (6 mT) and Pulsed Magnetic Fields (15 and 72 Hz)
Current Chemical Biology Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Unmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Prion Diseases: Time for a Therapy ?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Current Drug Targets Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets